الفهرس Only 14 pages are availabe for public view
 |  | from | 180 |  |  |
| | | from | 180 | | |
Abstract
Dogs are the most popular companion animal in Egypt. They could be affected dramatically by many diseases resulted in huge money losses especially among high breeds. Canine parvovirus 2 (CPV-2) is one of the most important viral enteric pathogen for both domestic and wild canids causing severe hemorrhagic enteritis all over the world since 1978. Due to the continuous evolution of the CPV-2, new antigenic variants always emerge causing increase infection in different ages and species. By time and with the emergence of new antigenic variants, this might lead to incidence of vaccination failure cases. Therefore, the efficacy of the current used CPV vaccine against these new variants has to be under further examination to follow up the virus continuous evolution. In the present study, 50 fecal swabs were collected from diseased unvaccinated dogs suffering from gastrointestinal disorders during a period from 2014 to 2015, from Cairo and Giza in Egypt. The collected samples were tested by immunochromatographic diagnostic kit, only 8 out of 50 samples were positive. The 8 positive samples were isolated and propagated in different cell lines (BHK-21, MDCK, and Vero cells). Only 6 out of 8 samples were positive and gave CPE in cell lines. The 6 positive samples were identified by fluorescent antibody technique and all were positive. The 6 samples were introduced to conventional PCR where the 6 samples gave positive bands in the gel electrophoresis. Only 2 positive canine parvovirus PCR products with the local field vaccinal strain (VSVRI vaccine) were sent for sequencing and comparing between them. According to the Genebank, the two samples were 100% homologous and 98% query coverage with each others. When compared to the local vaccinal strain, each sample was 99% homologous and 99% query coverage. Our data suggest that there is no need to change the local field vaccine (VSVRI). The two samples are closely related to CPV2a genotype